SEC Form 4 · accession 0001209191-15-004197
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberly J Popovits
Officer — President and CEO · Director
Period of report
Jan 12, 2015
Accepted (ET)
Jan 14, 2015 · 4:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 12, 2015 | M | 3,000 | $18.89 | A | 39,965 | D | |
| Common StockF1,F2,F3,F4 | Jan 12, 2015 | S | 3,000 | $33.4621 | D | 36,965 | D | |
| Common Stock | holding | — | — | — | 12,298 | I | Held by UBS for Benefit of Kimberly Popovits | |
| Common Stock | holding | — | — | — | 16,825 | I | Held in trust for the benefit of Ms. Popovits' son, of which Ms. Popovits is trustee. | |
| Common Stock | holding | — | — | — | 204,601 | I | Held by the Popovits 2010 Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F5 | $18.89 | Jan 12, 2015 | M | 3,000 | D | — | Nov 30, 2016 | Common Stock | 3,000 | 24,313 | D |
Explanation of responses
- F1These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on March 10, 2014.
- F2Represents weighted average sale price. Actual sale prices ranged from $33.11 to $33.71.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Includes an aggregate of 22,335 shares of common stock issuable pursuant to previously reported restricted stock unit awards that have not vested.
- F5The option became exercisable as to 25% of the shares on November 30, 2007, and becomes exercisable as to 1/48th of the shares each full month thereafter.